A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.
NCT ID: NCT00642577
Last Updated: 2022-12-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
214 participants
INTERVENTIONAL
2007-07-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
bevacizumab [Avastin]
5mg/kg iv every 2 weeks
irinotecan
125mg/m2 iv weekly for 4 weeks of each 6 week cycle
leucovorin
20mg/m2 iv weekly for 4 weeks of each 6 week cycle
fluorouracil
500mg/m2 iv weekly for 4 weeks of each 6 week cycle
2
irinotecan
125mg/m2 iv weekly for 4 weeks of each 6 week cycle
leucovorin
20mg/m2 iv weekly for 4 weeks of each 6 week cycle
fluorouracil
500mg/m2 iv weekly for 4 weeks of each 6 week cycle
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
bevacizumab [Avastin]
5mg/kg iv every 2 weeks
irinotecan
125mg/m2 iv weekly for 4 weeks of each 6 week cycle
leucovorin
20mg/m2 iv weekly for 4 weeks of each 6 week cycle
fluorouracil
500mg/m2 iv weekly for 4 weeks of each 6 week cycle
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* histologically confirmed adenocarcinoma of the colon or rectum, with metastatic disease;
* \>=1 measurable lesion;
* ECOG performance status of \<=1.
Exclusion Criteria
* adjuvant or neo-adjuvant treatment for non-metastatic disease in past 6 months;
* other malignancy within past 5 years, except cured basal cell cancer of skin or cured cancer in situ of cervix;
* clinically significant cardiovascular disease in past 6 months.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing, , China
Beijing, , China
Beijing, , China
Chongqing, , China
Guangdong, , China
Guangzhou, , China
Nanjing, , China
Qingdao, , China
Shanghai, , China
Shanghai, , China
Tianjin, , China
Wuhan, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BO20696
Identifier Type: -
Identifier Source: org_study_id